In:
Psychotherapy and Psychosomatics, S. Karger AG, Vol. 71, No. 3 ( 2002), p. 173-176
Abstract:
〈 i 〉 Background: 〈 /i 〉 Previous studies have suggested that posttraumatic stress disorder (PTSD) may be associated with pervasive sexual dysfunction. Sildenafil citrate was established as a highly effective and well-tolerated oral agent for the treatment of sexual dysfunction of various etiologies. There are no studies that have examined the efficacy of oral sildenafil in PTSD patients with sexual dysfunction. 〈 i 〉 Objective: 〈 /i 〉 The current study evaluated the impact of sildenafil added to an ongoing antidepressive treatment in male PTSD patients. 〈 i 〉 Methods: 〈 /i 〉 Ten consecutive male PTSD patients who complained of sexual dysfunction were enrolled in an open-label 4-week fixed-dose study of sildenafil citrate 50 mg/day p.r.n. Patients were evaluated at baseline and after treatment with the Clinician-Administered PTSD Scale (CAPS); sexual function assessments were performed using the International Index of Erectile Function. 〈 i 〉 Results: 〈 /i 〉 All patients completed the study and statistically significant improvement was observed in all evaluated domains of sexual functioning: erectile function (53.5%), orgasmic function (40.3%), sexual desire (53%), intercourse satisfaction (82%) and overall satisfaction (57.4%). Oral sildenafil treatment appeared to be well tolerated and no single patient stopped the treatment. Improvements in various CAPS subscales were also obtained; however, there was no significant correlation between improvement in sexual functioning and the changes in CAPS subscale scores. 〈 i 〉 Conclusion: 〈 /i 〉 Sildenafil seems to be an efficacious, safe and well-tolerated treatment of sexual dysfunction in antidepressant-treated male PTSD patients.
Type of Medium:
Online Resource
ISSN:
0033-3190
,
1423-0348
Language:
English
Publisher:
S. Karger AG
Publication Date:
2002
detail.hit.zdb_id:
1472321-9
SSG:
5,2
SSG:
15,3
Permalink